Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of TPN171H in Subjects with Hepatic Impairment
NCT05185011Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Dec 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TPN171H in erectile dysfunction (ED) and pulmonary arterial hypertension (PAH) (3 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area under the plasma concentration versus time curve extrapolated to infinity at 72 hours and 1 more. Started Dec 2021; status: completed.
02
Drugs
TPN171H
03
Conditions
erectile dysfunction (ED)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05185011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05185011.